Durham.

PositionTriangle

DURHAM -- Drug developer Chimerix signed a licensing deal with Whitehouse, N.J.-based pharmaceutical company Merck for an experimental HIV treatment. Chimerix will receive a $17.5 million upfront payment and can earn up to $151 million in milestone payments, as well as royalties from...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT